Srs Capital Advisors, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 356 shares of CPRX stock, worth $7,198. This represents 0.0% of its overall portfolio holdings.
Number of Shares
356Holding current value
$7,198% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$378 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$185 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$122 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$60.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.08B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...